Seegene, Inc. (KOSDAQ:096530)
25,700
+50 (0.19%)
At close: Dec 5, 2025
Seegene Revenue
Seegene had revenue of 113.54B KRW in the quarter ending September 30, 2025, with 4.34% growth. This brings the company's revenue in the last twelve months to 458.94B, up 14.90% year-over-year. In the year 2024, Seegene had annual revenue of 414.25B with 12.76% growth.
Revenue (ttm)
458.94B
Revenue Growth
+14.90%
P/S Ratio
2.58
Revenue / Employee
2.12B
Employees
216
Market Cap
1.19T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 414.25B | 46.88B | 12.76% |
| Dec 31, 2023 | 367.38B | -486.19B | -56.96% |
| Dec 31, 2022 | 853.56B | -517.27B | -37.73% |
| Dec 31, 2021 | 1.37T | 245.62B | 21.83% |
| Dec 31, 2020 | 1.13T | 1.00T | 822.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |